期刊文献+

周剂量多西紫杉醇联合小剂量顺铂、5-氟脲嘧啶持续静脉滴注治疗晚期胃癌的疗效观察 被引量:3

Observation of Weekly Dose of Docetaxel Combined with Small Doses of Cisplatin,5-Fluorouracil Continuous Intravenous Infusion Treatment of Advanced Gastric Cancer
下载PDF
导出
摘要 目的评价周剂量多西紫杉醇联合小剂量顺铂、5-氟脲嘧啶(5-Fu)持续静脉滴注治疗晚期胃癌的临床疗效和毒副反应。方法48例晚期胃癌随机分为两组,试验组:多西紫杉醇35 mg/(m2.d)静滴,d1,8,15;顺铂6 mg/(m2.d),d1~5,d8~12;5-Fu 250 mg/(m2.d)微量输液泵维持持续静滴,d1~14,3周为1周期。对照组:顺铂75 mg/(m2.d),d1静滴;5-Fu 1 000 mg/(m2.d),d1~5,3周为1周期。治疗3~4个周期后评价疗效和毒副反应。结果试验组总有效率为45.8%;对照组总有效率为37.5%。两组有效率比较差异无统计学意义(P>0.05)。试验组较对照组白细胞下降(79.2%vs 45.8%);试验组腹泻(41.6%vs 20.8%)较对照组明显升高(P<0.05);试验组恶心、呕吐的发生率(33.3%vs 12.5%)低于对照组,差异均有统计学意义(P<0.05)。结论多西紫杉醇联合小剂量顺铂、5-Fu持续静脉滴注治疗晚期胃癌具有较好的疗效,毒副反应可耐受,是晚期胃癌化疗的有效方案。 Objective To evaluate the clinical efficacy and toxicity of weekly dose docetaxel combined with small doses of cisplatin,5-fluorouracil(5-Fu) continuous infusion for treatment of advanced gastric cancer.Methods 48 cases with advanced gastric cancer were randomly divided into two groups,the test group(A group): docetaxel 35 mg/(m^2·d),d1,8,15,cisplatin 6 mg/(m^2·d),d1-5,d8-12;5-Fu 250 mg/(m^2·d) micro-infusion pump to maintain the continuous infusion,d1-14,three weeks for one cycle and the control group(B group): cisplatin 75 mg/(m^2·d),d1,5-Fu 1 000 mg/(m^2·d),d1-5,three weeks for one cycle.3-4 months after the treatment cycle evaluation of the efficacy and adverse reactions.Results The total effective rate of the test group was 45.8%,the total effective rate of the control group was 37.5%.Difference between the two groups had no obvious statistical significance(P〉0.05).The two groups had similar toxicity.In the hematological toxicity,the test group of patients with increased incidence of leukopenia(79.2% vs 45.8%).Non-hematological toxicity,there was higher incidence of diarrhea(41.6% vs 20.8%) in the test group(P〈0.05).In the control group,nausea and vomiting(33.3% vs 12.5%) had high incidence(P〈0.05).Conclusion Docetaxel combined with small doses of cisplatin,5-Fu continuous infusion for treatment of advanced gastric cancer has better efficacy,adverse reactions can be tolerated.This kind of chemotherapy is effective options for advanced gastric cancer.
出处 《肿瘤基础与临床》 2009年第4期318-320,共3页 journal of basic and clinical oncology
关键词 胃癌 多西紫杉醇 周剂量 5-氟脲嘧啶 持续滴注 gastric cancer docetaxel weekly dose 5-fluorouracil continuous intravenous infusion
  • 相关文献

参考文献6

  • 1Roth A D,Ajani J.Docetaxel-hased chemotherapy in the treatment of gastric cancer[J].Ann Oncol,2003,14 suppl 2:ii41 -44.
  • 2Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplatin with or without fl uorouracil in patients with untreated,advanced gastrie,or gastroesophageal adenocarcinoma[J].J Clin Oncol,2005,23 (24):5660-5667.
  • 3Ajani JA.Moiseyenko VM,Tjulandin S,et al.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase Ⅲ trial for advanced gastric or gastroeso-phageal adenocarcinoma:the V-325 Study Group[J].J Clin Oncol,2007,25(22):3210 -3216.
  • 4Ajani JA,Moiseyenko VM,Tiulandin S.et al.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase Ⅲ trial of advanced gastric or gastroesophageal cancer adenocarcinoma:the V-325 Study Group[J].J Clin Oncol,2007,25 (22):3205-3209.
  • 5Kim JH,Lee YC.Docetaxel-Cisplatin-5-Fu combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer[J].Korean J Gastroenterol,2007,50(3):207-209.
  • 6Both AD,Fazio N,Stupp R,et al.Docetaxel,cisplatin,and fluorouracil; dncetaxel and cisplatin ; and epirubiciu,cisplatin,and fluorouracil as systemic treatment for advanced gastric carcinoma:a randomized phase Ⅱ trial of the Swiss Group for Clinical Cancer Research[J].J Clin Oncol,2007,25(22):3217-3223.

同被引文献22

  • 1陈世壮,方晓敏,白艳春,刘静.多西紫杉醇加顺铂及氟尿嘧啶化疗辅助治疗进展期胃癌[J].实用医药杂志,2006,23(2):153-155. 被引量:2
  • 2刘云军,何志江.多西紫杉醇联合顺铂、5-氟脲嘧啶治疗晚期胃癌的疗效观察[J].广东医学院学报,2006,24(3):299-300. 被引量:5
  • 3郝代钧,樊建淑,张玲.多西紫杉醇联合奥沙利铂5-氟脲嘧啶和亚叶酸钙治疗晚期胃癌的临床研究[J].中国肿瘤临床,2007,34(16):953-955. 被引量:11
  • 4Roth A D, Maibach R, Martinelli G, et al. Docetaxel (taxotere R)-cisplatin(TC): an effective drug combina- tion in gastric carcinoma[J]. Ann Onc, 2000, 11(3): 301- 306.
  • 5AJANI J A, CUTSEM E V, ROTH A D, et al. Docetaxel(D), cis-platin, 5-fluorouracil compare to cisplatin(C) and 5-fluorouracil(F)for chemotherapy negative patients with metastatic or locally recur-rent, unresectable gastric carcinoma(MGC) Interrim results of arandomized phase III trial(V325)[J]. Proc Soc Clin Oncol, 2003, 22(6)999.
  • 6Homer M J, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975 - 2006. National Cancer Institute [EB/OL] (2008 - 10) [2009 - 05]. http://seer. cancer, gov/csr/1975_2006/.
  • 7Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapyFor advanced gastric cancer:a report of the V325 Study Group [ J ]. J Clin Oncol, 2006,24 ( 31 ) : 4991 - 4997.
  • 8Ajani JA. Docetaxel in combination for advanced gastric cancer [ J ]. Gastric Cancer,2002,5 ( Suppl 1 ) : 31 - 34.
  • 9Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual[ M]. 7th ed. New York: Springer-Verlag New York Inc,2010 : 11.
  • 10周际昌.实用肿瘤内科学[M].第1版.北京:北京科技出版社,2010:445.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部